natgillin/translations-raw huggingface dataset:
Dermatological reactions (including nail effects), observed in patients treated with Vectibix or other EGFR inhibitors, are known to be associated with the pharmacologic effects of therapy (with cross- reference to sections 4.2 and 4.8).
Znano je, da so dermatološke reakcije (vključno z učinki na nohte), ki so jih opažali pri bolnikih, zdravljenih z zdravilom Vectibix ali drugimi zaviralci EGFR, povezane s farmakološkimi učinki takšnega zdravljenja (s sklicem na poglavji 4.2 in 4.8).
Dermatological reactions (including nail effects), observed in patients treated with Vectibix or other EGFR inhibitors, are known to be associated with the pharmacologic effects of therapy.
Znano je, da so dermatološke reakcije (vključno z učinki na nohte), ki so jih opažali pri bolnikih, zdravljenih z zdravilom Vectibix ali drugimi zaviralci EGFR, povezane s farmakološkimi učinki takšnega zdravljenja.
Dermatological toxicity
Škodljivi učinki na kožo
Dermatologist Static Global Assessment.
Dermatološka statična splošna ocena.
Derzsy’s disease is a similar infection caused by the closely related virus, goose parvovirus.
Derzsyjeva bolezen je podobna okužba, ki jo povzroča zelo soroden virus – parvovirus gosi.
DESCARTES was an international, multicentre, double-blind, randomised, placebo-controlled, 52-week study in 901 patients with hyperlipidaemia who received diet alone, atorvastatin, or a combination of atorvastatin and ezetimibe.
DESCARTES je bila mednarodna, multicentrična, dvojno slepa, randomizirana, s placebom kontrolirana, 52-tedenska študija pri bolnikih (n = 901) s hiperlipidemijo, ki so uporabljali samo dieto, atorvastatin ali kombinacijo atorvastatina in ezetimiba.
Descovy 200 mg/10 mg [Outer packaging only]
Descovy 200 mg/10 mg [samo na zunanji ovojnini]
Descovy 200 mg/10 mg film-coated tablets
Descovy 200 mg/10 mg filmsko obložene tablete
Descovy 200 mg/10 mg film-coated tablets emtricitabine/tenofovir alafenamide
Descovy 200 mg/10 mg filmsko obložene tablete emtricitabin/alafenamidtenofovirat
Descovy 200 mg/25 mg [Outer packaging only]
Descovy 200 mg/25 mg [samo na zunanji ovojnini]
Descovy 200 mg/25 mg film-coated tablets
Descovy 200 mg/25 mg filmsko obložene tablete
Descovy 200 mg/25 mg film-coated tablets emtricitabine/tenofovir alafenamide
Descovy 200 mg/25 mg filmsko obložene tablete emtricitabin/alafenamidtenofovirat
Descovy can cause dizziness.
Zdravilo Descovy lahko povzroči omotičnost.
Descovy contains two active substances:
Zdravilo Descovy vsebuje dve zdravilni učinkovini:
Descovy film-coated tablets are blue, rectangular-shaped tablets, debossed on one side with “GSI” and the number “225” on the other side of the tablet.
Zdravilo Descovy filmsko obložene tablete so modre tablete pravokotne oblike z vtisnjenim znakom “GSI” na eni strani in številko “225” na drugi strani.
Descovy has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore, Descovy is not recommended for use in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Zdravila Descovy niso preučili pri bolnikih s hudo jetrno okvaro (stopnje C po Child-Pughu); zato se uporaba zdravila Descovy pri bolnikih s hudo jetrno okvaro ne priporoča (glejte poglavji 4.4 in 5.2).
Descovy should be administered as shown in Table 1.
Zdravilo Descovy je treba dajati, kot je prikazano v preglednici 1.
Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).
Zdravljenje z zdravilom Descovy je treba prekiniti pri bolnikih z ocenjenim CrCl, ki med zdravljenjem pade pod 30 ml/min (glejte poglavji 5.1 in 5.2).
Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Zdravilo Descovy se sme med nosečnostjo uporabljati samo, če možne koristi upravičujejo možno tveganje za plod.
Descovy should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), emtricitabine, lamivudine or adefovir dipivoxil.
Zdravila Descovy se ne sme dajati skupaj z zdravili, ki vsebujejo dizoproksiltenofovirat (v obliki fumarata), emtricitabin, lamivudin ali dipivoksiladefovirat.
Descovy should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Zdravila Descovy se ne sme dajati skupaj z zdravili, ki vsebujejo dizoproksiltenofovirat (v obliki fumarata), lamivudin ali dipivoksiladefovirat, ki se uporabljajo za zdravljenje okužbe s HBV.
Descovy should not be initiated in patients with estimated CrCl < 30 mL/min as there are limited data available regarding the use of Descovy in this population (see sections 5.1 and 5.2).
Zdravila Descovy se ne sme uvesti pri bolnikih z ocenjenim CrCl < 30 ml/min, saj so podatki glede uporabe zdravila Descovy pri tej populaciji omejeni (glejte poglavji 5.1 in 5.2).
Description
Lýsing
Description and management of infections, dizziness and confusion, tumor lysis syndrome, allergic reactions, hepatic disorders, cardiac failure and interstitial lung disease o
opis in obravnavanje infekcij, omotičnosti in zmedenosti, sindroma tumorske lize, alergijskih reakcij, bolezni jeter, popuščanja srca in intersticijske pljučne bolezni,
Description and management of neutropenia and thrombocytopenia including incidence rates from clinical trials
opis ter obravnavanje nevtropenije in trombocitopenije, vključno s stopnjo incidence v kliničnih študijah,
Description and management of thromboembolic risk including incidence rates from clinical trials and post-marketing experience
opis in obravnavanje trombemboličnega tveganja, vključno s stopnjo incidence v kliničnih preskušanjih in izkušnje po začetku trženja,
Description and management of thromboembolic risk including incidence rates from clinical trials and post-marketing experience
opis in obravnavanje trombemboličnega tveganja, vključno s stopnjo incidence v kliničnih študijah in izkušnje po začetku trženja,
Description and management of venous and arterial thromboembolic events, cardiovascular events, and peripheral neuropathy
opis in upravljanje venskih in arterijskih trombemboličnih dogodkov kardiovaskularnih dogodkov in periferne nevropatije
Description of available deferasirox formulations
opis formulacij zdravila z deferasiroksom, ki so na voljo
Description of cardiorespiratory disorders including incidence rates from clinical trials
Opis kardiorespiratornih obolenj, vključno s stopnjami incidence iz kliničnih preskušanj
Description of post injection syndrome
Opis sindroma po injiciranju
Description of reconstitution and proper administration technique
Opis rekonstitucije in pravilnih tehnik injiciranja
Description of selected adverse drug reactions
Povzetek glavnih značilnosti zdravila
Description of selected Adverse Drug Reactions (ADRs)
Opis izbranih neželenih učinkov
Description of selected adverse reactions
Opis izbranih neželenih učinkih
Description of selected adverse reactions
Opis izbranih neželenih učinkov zdravila
Description of selected adverse reactions
Opis izbranih neželenih učinov
Description of selected adverse reactions
Opis označenega neželenega učinka
Description of selected adverse reactions
Opisizbranih neželenih učinkov
Description of selected adverse reactions Aseptic meningitis
Opis posameznih neželenih učinkov Aseptični meningitis
Description of selected adverse reactions Class effects:
Opis izbranih neželenih učinkov Učinki po skupinah:
Description of selected adverse reactions Dapagliflozin plus metformin Hypoglycaemia
Opis izbranih neželenih učinkov Dapagliflozin skupaj z metforminom Hipoglikemija
Description of selected adverse reactions Drug hypersensitivity reactions:
Opis izbranih neželenih učinkov Preobčutljivostne reakcije na zdravilo:
Description of selected adverse reactions for adjuvant therapy with Docetaxel 75 mg/m2 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316 and node-negative (GEICAM 9805) breast cancer
Opis izbranih neţelenih učinkov adjuvantnega zdravljenja z zdravilom Docetaxel Teva Pharma 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions for adjuvant therapy with Docetaxel 75 mg/m2 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neţelenih učinkov adjuvantnega zdravljenja z zdravilom Docetaxel Teva Pharma 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions for adjuvant therapy with Docetaxel 75 mg/m2 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaksel 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaksel 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions for adjuvant therapy with Docetaxel Winthrop 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaxel Winthrop 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions for adjuvant therapy with Taxespira 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom Taxespira75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions for adjuvant therapy with Taxotere 75 mg/m2 in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom TAXOTERE 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions Herpes zoster virus reactivation Multiple myeloma
Opis izbranih neželenih učinkov Reaktivacija virusa herpes zoster Diseminirani plazmocitom
Description of selected adverse reactions in breast cancer for adjuvant therapy with TAXOTERE 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom TAXOTERE 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of selected adverse reactions in breast cancer for Docetaxel 100 mg/m2 in combination with trastuzumab
Opis izbranih neţelenih učinkov zdravljenja z zdravilom Docetaxel Teva Pharma 100 mg/m2 pri raku dojke v kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel 100 mg/m2 single agent
Opis izbranih neţelenih učinkov monoterapije z zdravilom Docetaxel Teva Pharma 100 mg/m2 pri raku dojke
Description of selected adverse reactions in breast cancer for Docetaxel 100 mg/m2 single agent
Opis izbranih neželenih učinkov monoterapije z zdravilom Docetaksel 100 mg/m2 pri raku dojke
Description of selected adverse reactions in breast cancer for Docetaxel 100 mg/m2 single agent
Opis izbranih neželenih učinkov monoterapije z zdravilom Docetaksel 100 mg/m² pri raku dojke
Description of selected adverse reactions in breast cancer for Docetaxel 100 mg/m² in combination with trastuzumab
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaksel 100 mg/m² raku dojke v kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m2 in combination with trastuzumab
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaxel Winthrop 100 mg/m2 pri raku dojke v kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m2 single agent
Opis izbranih neželenih učinkov monoterapije z zdravilom Docetaxel Winthrop 100 mg/m2 pri raku dojke
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m² in combination with trastuzumab
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaxel Winthrop 100 mg/m2 pri raku dojke v kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m² in combination with trastuzumab
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaxel Winthrop 100 mg/m2 pri raku dojke v kombinaciji z trastuzumabom
Description of selected adverse reactions in breast cancer for Docetaxel Winthrop 100 mg/m² single agent
Opis izbranih neželenih učinkov monoterapije z zdravilom Docetaxel Winthrop 100 mg/m2 pri raku dojke
Description of selected adverse reactions in breast cancer for Taxespira 100 mg/m2 in combination with trastuzumab
Opis izbranih neželenih učinkov zdravljenja z zdravilom Taxespira100 mg/m pri raku dojke v kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for Taxotere 100 mg/m2 in combination with trastuzumab
Opis izbranih neželenih učinkov zdravljenja z zdravilom TAXOTERE 100 mg/m2 pri raku dojke v kombinaciji s trastuzumabom
Description of selected adverse reactions in breast cancer for TAXOTERE 100 mg/m2 single agent
Opis izbranih neželenih učinkov monoterapije z zdravilom TAXOTERE 100 mg/m2 pri raku dojke
Description of selected adverse reactions in children and adolescents
Opis izbranih neželenih učinkov pri otrocih in mladostnikih
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis izbranih neţelenih učinkov zdravljenja z zdravilom Docetaxel Teva Pharma 75 mg/m2 v kombinaciji s cisplatinom in 5-fluorouracilom za adenokarcinom ţelodca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis izbranih neţelenih učinkov zdravljenja z zdravilom Docetaxel Teva Pharma 75 mg/m2 v kombinaciji scisplatinom in 5-fluorouracilom za adenokarcinom ţelodca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaksel 75 mg/m2 v kombinaciji scisplatinom in 5-fluorouracilom za adenokarcinom želodca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Tabelarični prikaz neželenih učinkov zdravljenja z zdravilom Docetaksel 75 mg/m² v kombinaciji s cisplatinom in 5-fluorouracilom za adenokarcinom želodca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel Winthrop 75 mg/m2 in combination with ciplatin and 5-fluorouracil
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaxel Winthrop 75 mg/m2 v kombinaciji s cisplatinom in 5-fluorouracilom za adenokarcinom želodca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel Winthrop 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaxel Winthrop 75 mg/m2 v kombinaciji s cisplatinom in 5-fluorouracilom za adenokarcinom želodca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Docetaxel Winthrop 75 mg/m² in combination with cisplatin and 5-fluorouracil
Opis izbranih neželenih učinkov zdravljenja z zdravilom Docetaxel Winthrop 75 mg/m2 v kombinaciji s cisplatinom in 5-fluorouracilom za adenokarcinom želodca
Description of selected adverse reactions in gastric adenocarcinoma cancer for Taxespira 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Opis izbranih neželenih učinkov zdravljenja z zdravilom Taxespira75 mg/m2 v kombinaciji s cisplatinom in 5-fluorouracilom pri adenokarcinomu želodca
Description of selected adverse reactions Inhibitor Development
Opis izbranih neželenih učinkov Nastanek zaviralcev
Description of selected adverse reactions Mitochondrial toxicity
Opis izbranih neželenih učinkov Toksičnost za mitohondrije:
Description of selected adverse reactions observed with other PDE5 inhibitors
Opis nekaterih neželenih učinkov, o katerih so poročali pri uporabi drugih zaviralcev PDE5
Description of selected adverse reactions observed with Zutectra
Opis izbranih neželenih učinkov
Description of selected adverse reactions).
Opis nekaterih neželenih učinkov).
Description of selected of adverse reactions for adjuvant therapy with Docetaxel Winthrop 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom Docetaxel Winthrop 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Description of the administration procedures of BLINCYTO
Opis postopkov dajanja zdravila BLINCYTO.
Description of the administration procedures of BLINCYTO and how to reduce the risk of ME while using the infusion pump.
Opis postopkov dajanja zdravila BLINCYTO in kako zmanjšati tveganje za napake pri uporabi zdravila, med uporabo infuzijske črpalke.
Description of the administration system
Opis aplikacijskega sistema
Description of the key differences between Kadcyla and Herceptin in relation to indication, dose, administration and packaging differences.
Opis glavnih razlik med zdravilom Kadclya in zdravilom Herceptin glede indikacij, odmerka, aplikacije in ovojnine.
Description of the main signs and / or symptoms of neurologic events and the importance of notifying the treating physician or nurse immediately if symptoms occur
Opis glavnih znakov in / ali simptomov nevroloških učinkov in pomembnost, da takoj obvesti lečečega zdravnika ali medicinsko sestro, če se pojavijo simptomi.
Description of the main signs or symptoms of the irARs and the importance of notifying their treating physician immediately if symptoms occur
Opis glavnih znakov in simptomov imunsko pogojenih neželenih učinkov in opozorilo, da zdravnika obvestijo takoj, ko se simptomi pojavijo
Description of the main symptoms of irARs and the importance of notifying their treating physician immediately if symptoms occur, persist or worsen.
Opis glavnih simptomov imunsko pogojenih neželenih učinkov in pomembnost, da bolnik o njih nemudoma obvesti svojega zdravnika, če se simptomi pojavijo, vztrajajo ali poslabšajo.
Description of the most common symptoms reported with olanzapine overdose that represent the clinical manifestation in post injection syndrome events
Opis najpogostejših simptomov, ki so jih poročali pri prevelikem odmerjanju olanzapina in predstavljajo klinično izražene učinke pri sindromu po injiciranju
Description of the patient card and its necessity
opis kartice bolnika in razlago, zakaj je nujna;
Description of the patient card and its necessity
opis kartice bolnika in razlago, zakaj je potrebna;
Description of the patient card and its use in the individual Member State
opis kartice za bolnika in njeno uporabo v posameznih državah članicah
Description of the patient population treated in clinical studies
Opis populacije bolnikov, ki so jih zdravili v kliničnih študijah
Description of the patient reminder card
Opis bolnikove opomnilne kartice
Description of the pregnancy prevention programme
opis programa za preprečevanje zanositve
Description of the pregnancy prevention programme and categorisation of patients based on sex and childbearing potential
opis programa preprečevanja nosečnosti in kategorizacijo bolnikov glede na spol in zmožnost zanositve
Description of the pregnancy prevention programme and categorisation of patients based on sex and childbearing potential
opis programa preprečevanja zanositve in kategorizacijo bolnikov glede na spol in rodno dobo
Description of thromboembolic events including incidence rates from clinical trials
Opis trombemboličnih dogodkov, vključno s stopnjami incidence iz kliničnih preskušanj
Description on patient’s monitoring and management of early signs and symptoms of neurological events
Opis za spremljanje bolnikov in obvladovanje zgodnjih znakov in simptomov nevroloških učinkov.
Desensitization can be accomplished by starting with 10 mg para-aminosalicylic acid given as a single dose.
Desenzibilizacijo je mogoče doseči tako, da se na začetku zdravljenja daje 10 mg para-aminosalicilne kisline v enkratnem odmerku.
Desiccant (one pouch or two pouches) is added.
V plastenko je dodano sušilno sredstvo (1 ali 2 vrečki).
Design
Zasnova
Design: randomised (1:1), double-blinded, placebo-controlled.
Načrt: randomizirano (1:1), dvojno slepo in s placebom nadzorovano preskušanje.
Design: randomised, global multicentre, double-blind, placebo-controlled Treatment: Viekirax and dasabuvir with weight-based ribavirin for 12 weeks
Oblika preskušanja: randomizirano, globalno, multicentrično, dvojno slepo, s placebom kontrolirano Zdravljenje: Viekirax in dasabuvir z ribavirinom, odvisnim od telesne mase, 12 tednov
Design: randomised, global multicentre, open-label
Oblika preskušanja: randomizirano, globalno, multicentrično, odprto
Desipramine
1,03 (1,00; 1,06)
Desipramine
Desipramin
Desipramine 100, single oral dose 500 q12h ↑ 145% ↑ 22%
100, posamičen 500 na 12 ur ↑ 145 % ↑ 22 % peroralni odmerek
desipramine, nortriptyline, paroxetine and similar medicines (used to treat depression)
dezipramin, nortriptilin, paroksetin in podobna zdravila (uporabljamo jih za zdravljenje depresije)
desipramine, trazodone and bupropion (used to treat depression; bupropion is also used for smoking cessation)
desipramina, trazodona in bupropiona (za zdravljenje depresije; bupropion uporabljajo tudi za odvajanje od kajenja),
desipramine, trazodone and bupropion (used to treat depression; bupropion is also used for smoking cessation)
desipramina, trazodona in bupropiona (za zdravljenje depresije; bupropion uporabljajo tudi za odvajanje od kajenja);
Desipramine: Concurrent administration of 90 mg cinacalcet once daily with 50 mg desipramine, a tricyclic antidepressant metabolised primarily by CYP2D6, significantly increased desipramine exposure 3.6-fold (90 % CI 3.0, 4.4) in CYP2D6 extensive metabolisers.
Dezipramin: Sočasna uporaba 90 mg cinakalceta enkrat na dan in 50 mg dezipramina (tricikličnega antidepresiva, ki se primarno presnavlja s CYP2D6) je pri izrazitih metabolizatorjih s CYP2D6 izpostavljenost dezipraminu povečala značilno, in sicer za 3,6-krat (90 % IZ: 3,0, 4,4).